Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice – results from the prospective German TMK cohort study. 18. Dezember 2017 N Marschner, T Fietz, J Rauh, A Nusch, U Söling, M Frank, L Kruggel, M Jänicke, 2017. The Breast, Volume 36, S45 https://doi.org/10.1016/S0960-9776(17)30688-4 Abstract Bevacizumab (Bev)-based combination therapy across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC)-interim analysis results from a German non-interventional study (KORALLE). Eggers, E., Uhlig, J., Reichert, D., Wein, A., Schulz, H., Behringer, A., Arnold, D., 2017. Oncol Res Treat, 40(suppl 3)(P577), 162-163. Weiterlesen Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC). Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017. Ann Oncol… Weiterlesen